Just a year in and $25M down, Eli Lilly abruptly exits NextCure pact

Lilly
The pact was penned back in late 2018 but has now been axed (Eli Lilly/LinkedIn).

Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago, with no details as to why.

That deal, which also included undisclosed milestones, was built upon a platform for scouring cell surface interactions in search of targets that affect immune function with NextCure, which is staffed by executives who led Amplimmune to a takeover by AstraZeneca.

I-O laggard Lilly was hoping this, with other recent buys, would help shore up its cancer pipeline, and saw the Big Pharma pay $25 million upfront and take out a $15 million stake in NextCure for the chance to access the fruits of the platform.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

In return, Lilly bagged an option to exclusively license antibodies against targets discovered using NextCure’s platform and NextCure had the option to license antibodies, too, and could have got milestones and royalties of undisclosed size if the drugs Lilly picks up progress.

Now, that’s been axed.

In an extremely brief SEC update (and no press release at time of writing), Maryland-based NextCure said: “On January 10, 2020, Eli Lilly and Company notified NextCure of Lilly’s termination, effective as of March 3, 2020, of the Research and Development Collaboration Agreement, dated as of November 2, 2018, between the Company and Lilly.”

The biotech is presenting at the J.P. Moran Healthcare Conference this Thursday, where more information will (hopefully) be forthcoming as no explanation has been given. NextCure saw its shares down 6% shortly after the SEC filing was released Monday morning, and was still in the red Tuesday.

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.